Logo 1 Logo 2

Clinical Trial Details

Trial ID: L1527
Source ID: NCT03771729
Associated Drug: Lcz 696
Title: Observation on the Effect of Sacubitril/Valsartan in Advanced Chronic Kidney Disease(CKD)Patients With Heart Failure
Acronym:
Status: UNKNOWN
Study Results: NO
Results:
Conditions: CKD
Interventions: DRUG: LCZ 696
Outcome Measures: Primary: Change in estimated glomerular filtration rate(eGFR), Blood samples will be collected for analysis of glomerular filtration rate(eGFR) every 2weeks ., 12 weeks|Change in urinary microalbumin/creatinine ratio(uACR), Urine samples will be collected for analysis of urinary microalbumin/creatinine ratio(uACR) every 2weeks., 12 weeks|Concentration of N terminal pro B type natriuretic peptide(NT-prpBNP), Blood samples will be collected for analysis of concentration of N terminal pro B type natriuretic peptide(NT-proBNP) every 2weeks., 12 weeks | Secondary: blood uric acid, Blood samples will be collected for analysis of uric acid every 2weeks., 12 weeks|Rate of HbA1c, Blood samples will be collected for analysis of HbA1c every 2weeks., 12weeks|Systolic and diastolic blood pressure, Systolic and diastolic blood pressure will be measured every 2weeks., 12 weeks|left ventricle eject fraction, Cardiac ultrasound will be measured every 2weeks., 12 weeks|Concentration of postassium, Blood samples will be collected for analysis of concentration of postassium every 2weeks., 12 weeks|Concentration of serum troponin, Blood samples will be collected for analysis of concentration of serum troponin every 2weeks., 12 weeks|Concentration of alanine aminotransferase or aspartate aminotransferase, Blood samples will be collected for analysis of concentration of alanine aminotransferase or aspartate aminotransferase every 2weeks., 12 weeks|Concentration of sodio, Urine samples will be collected for analysis of concentration of sodion every 2weeks., 12 weeks
Sponsor/Collaborators: Sponsor: The Second Affiliated Hospital of Harbin Medical University
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: EARLY_PHASE1
Enrollment: 30
Study Type: INTERVENTIONAL
Study Designs: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2018-12-30
Completion Date: 2019-06-15
Results First Posted:
Last Update Posted: 2018-12-11
Locations:
URL: https://clinicaltrials.gov/show/NCT03771729